Target intelligence / Profile preview

D-alanyl-D-alanine terminus of peptidoglycan precursor lipid II (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Peptidoglycan component, Lipid II, Other
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the peptidoglycan precursor lipid II is a critical structural motif in the assembly of the Gram-positive bacterial cell wall (Source: Nature Reviews Microbiology, 2008). Lipid II serves as the essential carrier that transports peptidoglycan subunits across the cytoplasmic membrane to the site of cell wall synthesis. The D-Ala-D-Ala dipeptide at the end of the pentapeptide chain is the specific substrate recognized by transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of the peptidoglycan layer. This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin (Source: StatPearls, 2023). By binding with high affinity to this dipeptide via five hydrogen bonds, these drugs sterically hinder the enzymatic reactions required for cell wall polymerization, ultimately leading to bacterial cell death. Resistance to these antibiotics often involves the modification of this target to D-alanyl-D-lactate or D-alanyl-D-serine, which significantly reduces drug binding affinity (Source: Clinical Microbiology Reviews, 2019). This target is unique to bacteria, providing a high degree of selective toxicity for therapeutic intervention.

Other names
D-Ala-D-AlaD-alanyl-D-alanine dipeptidePeptidoglycan precursor terminusLipid II D-Ala-D-Ala
02

Mechanism of action

Glycopeptide antibiotics bind to the D-alanyl-D-alanine terminus of the peptidoglycan precursor lipid II via five hydrogen bonds. This binding sterically inhibits the transglycosylation and transpeptidation steps of peptidoglycan synthesis, preventing the cross-linking of the bacterial cell wall and leading to cell lysis (Source: StatPearls, 2023).

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingBacterial cell wall assemblyOther
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndromeDevelopment of Vancomycin-Resistant Enterococci (VRE)Development of Vancomycin-Resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

vanA genevanB genevanC geneMinimum Inhibitory Concentration (MIC) for vancomycin

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of peptidoglycan precursor lipid II (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursor lipid II (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call